CIA
BIIB icon

Cladis Investment Advisory’s Biogen BIIB Stock Holding History

Cladis Investment Advisory’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Buy
+1,040
New +$199K 0.11% 158
2026
Q1 		– Sell
-1,040
Closed -$183K – 161
2025
Q4 		$183K Buy
+1,040
New +$170K 0.1% 152

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cladis Investment Advisory's BIIB Position: Q2 2026 in Review

Cladis Investment Advisory opened a new position in Biogen (BIIB) in Q2 2026: 1,040 shares worth $225K. The stake represents 0.11% of the portfolio and ranks #158 among its holdings. This is a return to the name: Cladis Investment Advisory previously reported a position in BIIB as recently as Q4 2025.

Cladis Investment Advisory first reported a position in BIIB in Q4 2025 and has held it in 2 quarters since. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Cladis Investment Advisory held 1,040 shares of Biogen worth $225K as of Q2 2026.
  • Biogen was a new Cladis Investment Advisory position in Q2 2026.
  • Biogen made up 0.11% of Cladis Investment Advisory's portfolio in Q2 2026, its #158 holding.
  • Cladis Investment Advisory first reported a position in Biogen in Q4 2025 and has held it in 2 quarters since.
  • 1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Cladis Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.